jack412
Expert
- Messages
- 5,618
- Type of diabetes
- Type 2
- Treatment type
- Tablets (oral)
click ‘view’ right hand side to read report
http://www.researchgate.net/publica...olled_trials_to_aid_individual_patient_choice
Results: Among 14 primary prevention trials (46,262 participants),
statin therapy increased diabetes by absolute risk of 0.5% (95% CI 0.1–1%, p¼0.012),
meanwhile reducing death by a similar extent: 0.5% (0.9 to 0.2%, p¼0.003).
In the 15 secondary prevention RCTs (37,618 participants), statins decreased death by 1.4% (2.1 to 0.7%, p<0.001).
There were no other statin-attributable symptoms,
although asymptomatic liver transaminase elevation was 0.4% more frequent with statins across all trials. Serious adverse events and withdrawals were similar in both arms.
Conclusions:
Only a small minority of symptoms reported on statins are genuinely due to the statins:
almost all would occur just as frequently on placebo.
Only development of new-onset diabetes mellitus was significantly higher on statins than placebo; nevertheless only 1 in 5 of new cases were actually caused by statins. Higher statin doses produce a detectable effect, but even still the proportion attributable to statins is variable: for asymptomatic liver enzyme elevation, the majority are attributable to the higher dose; in contrast for muscle aches, the majority are not.
this study looked at the history of 60,000 Diabetics after av. 2.7
http://www.thelancet.com/journals/landia/article/PIIS2213-8587(14)70173-1/abstract
retinopathy HR=0.6 [decrease of risk]
neuropathy HR=0.66
gangrene of the foot HR=0.88
diabetic nephropathy HR=0.97
[neutral..........HR=1.0 ]
diabetes HR=1·17 [increase of risk]
the way I look at it ..if nothing else take statin for neuropathy, retinopathy and gangrene of the foot
http://www.researchgate.net/publica...olled_trials_to_aid_individual_patient_choice
Results: Among 14 primary prevention trials (46,262 participants),
statin therapy increased diabetes by absolute risk of 0.5% (95% CI 0.1–1%, p¼0.012),
meanwhile reducing death by a similar extent: 0.5% (0.9 to 0.2%, p¼0.003).
In the 15 secondary prevention RCTs (37,618 participants), statins decreased death by 1.4% (2.1 to 0.7%, p<0.001).
There were no other statin-attributable symptoms,
although asymptomatic liver transaminase elevation was 0.4% more frequent with statins across all trials. Serious adverse events and withdrawals were similar in both arms.
Conclusions:
Only a small minority of symptoms reported on statins are genuinely due to the statins:
almost all would occur just as frequently on placebo.
Only development of new-onset diabetes mellitus was significantly higher on statins than placebo; nevertheless only 1 in 5 of new cases were actually caused by statins. Higher statin doses produce a detectable effect, but even still the proportion attributable to statins is variable: for asymptomatic liver enzyme elevation, the majority are attributable to the higher dose; in contrast for muscle aches, the majority are not.
this study looked at the history of 60,000 Diabetics after av. 2.7
http://www.thelancet.com/journals/landia/article/PIIS2213-8587(14)70173-1/abstract
retinopathy HR=0.6 [decrease of risk]
neuropathy HR=0.66
gangrene of the foot HR=0.88
diabetic nephropathy HR=0.97
[neutral..........HR=1.0 ]
diabetes HR=1·17 [increase of risk]
the way I look at it ..if nothing else take statin for neuropathy, retinopathy and gangrene of the foot
Last edited by a moderator: